High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. by de Vries, T. J. et al.
Bntish Joumai of Cancer(1998) 78(9). 1156-1161
C 1998 Cancer Research Carpaign
High expression of immunotherapy candidate proteins
gpl00, MART-I, tyrosinase and TRP-I in uveal
melanoma
TJ de Vnes', D Trancilkova12, DJ Ruiter' and GNP van Muijen1
'Departnment of Pathology, University Hospital, PO Box 9101, 6500 HB Nijmegen. The Netherlands; 2Cancer Research Institute. Slovak Academy of Sciences.
Vlarska 7. Bratislava. SK 833 91 Slovakia
Summary In the treatment of cutaneous melanoma, provisional therapeutic strategies have been designed to combat tumour load using
T cells that are sensitized with peptides derived from melanoma autoantigens, such as glycoprotein 100 (gp100), melanoma antigen
recognized by T cells 1 (MART-1 or MelanA), tyrosinase and tyrosinase-related protein 1 (TRP-1). We recently found that gpl00, MART-1 and
tyrosinase are heterogeneously expressed in human cutaneous melanoma (De Vries et al (1997) Cancer Res 57: 3223-3229). Here, we
extended our investigations on expression of these immunotherapy candidate proteins to uveal melanoma lesions. Cryostat sections from 11
spindle-type, 21 mixed and epithelioid tumours and four metastasis lesions were stained with antibodies specifically recognizing gp100,
MART-1, tyrosinase and TRP-1. In addition, we used the DOPA reaction to detect tyrosinase enzyme activity as a confirmation of the
tyrosinase immunohistochemical results. High expression of gp100, MART-1 and tyrosinase was found in the uveal melanoma lesions: 80%
of the lesions displayed 75-100% positive tumour cells. TRP-1 positivity was slightly less: approximately 65% of the lesions stained in the
75-100% positive tumour cell category. All uveal melanoma lesions were positive for the four markers studied, this being in contrast to
cutaneous melanoma where 17% of the advanced primary lesions and metastases were negative. The presence of these antigens was a little
lower in metastases. We conclude that uveal melanomas and their metastases express melanocyte-lineage immunotherapy candidate
proteins very abundantly. Uveal melanomas differ in this respect from cutaneous melanoma, in which the expression of these immunotherapy
antigens was much more heterogeneous. This makes uveal melanoma a suitable candidate tumour for immunotherapeutic approaches.
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Most. if not all melanocv-te-lineage antigens were original1v
descnrbed and characterized from cutaneous melanoma sources.
Subsequent immunohistochemical studies on uxeal melanoma
lesions revealed that expression of these antigens. such as gplOO
(Van der Pol et al. 1987: Ringens et al. 1989: Steuhl et al. 1993).
S100 (Kan-Mitchel et al. 1990) and high molecular weigaht
melanoma-associated antigen (HMW-MAA) (Natali et al. 1989)
also occured in uveal melanoma cells. Furthermore. these antigens
were found in a high percentage of the lesions studied and w-ithin
these lesions a high percentage of tumour cells showed expression
ofthese antigens.
Monoclonal antibodies against gplOO has-e successfullv been
implemented in diagnostic pathology of cutaneous and uveal
melanoma (Carrel and Rimoldi. 1993: Ruiter and Brocker. 1993).
Antibodies against three other melanoma antigens. MART-I (Chen
et al. 1996). tyrosinase (Chen et al. 1995) and TRP-1 (Chen et al.
1995) have recentlx been described. The recent discoxerx that
peptides derived from gplOO (Bakker et al. 1994). MART-1
(Kaxwakami et al. 1994). txTosinase (Brichard et al. 1993) and
TRP-1 (Wang et al. 1996) can evoke tumour-specific immune
responses in cutaneous melanoma patients has put the immunohis-
tochemical evaluation of melanocv-tic lesions into a new perspec-
tive. as one of the main predictors of successful immunotherapx is
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the extent ofexpression ofthe target proteins. Another recent appli-
cation of melanoma antigens is in detection of circulating
melanoma cells (Smith et al. 1991). A reverse transcription-polN-
merase chain reaction (RT-PCR) detecting tyTosmnase transcripts in
cells isolated from blood ofuveal melanoma patients has been used
Awith a varving success rate (Tobal et al. 1993: Foss et al. 1995).
For both those who design immunotherapy protocols and those
who perform RT-PCRs based on the presence of melanoma-
specific mRNA in patients blood, it is important to knoxx the
content ofthese antigens in primary tumours. Recentlv. we studied
the presence of gp100. MART-1 and tyrosinase in cutaneous
melanocvtic lesions. We found that approximately 20% of the
adxanced primary tumours and metastases lacked expression of
these proteins (De Vries et al. 1997). Until now. nothing has been
known about the extent of expression of MART-1. tyrosinase and
TRP-1 in uxeal melanoma lesions. albeit that mRNA of three of
these markers has been detected in uveal melanomas (Mulcahv et
al. 1996). In this paper. we demonstrate the marked expression of
these potential targets for immunotherapy in 32 primary uveal
melanomas (11 spindle-type: 21 mixed and epithelioid tumours)
and in four uveal melanoma metastases.
MATERIALS AND METHODS
Tissue specimens
Representatixe tissue samples A-ere freshly received from uveal
melanocvtic lesions excised from patients at the Unixersitx
Hospital. Nijmegen. The Netherlands. They were snap frozen in
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liquid nitrogen and stored at -80°C until 4-pm cryostat sections
were cut. Haematoxylin and eosin-stained paraffin sections of
these lesions were used for classification. Based on cellular
morphology, we distinguished two groups ofpnmary tumours: 11
were of pure spindle cell type whereas 21 contained epithelioid
cells. Tumours with epithelioid cells have a worse prognosis
(Gamel et al, 1993). The four metastases were from different
patients and were excised from the parotid gland, lymph node,
brain and skin.
Antibodies and immunohistochemistry
NKI-beteb (Monosan/Sanbio, Uden, The Netherlands) and HMB-
45 (Dako, Glostrup, Denmark) were used as antibodies against
gplOO (Adema et al, 1993), A103 (Chen et al, 1996) was used as
antibody against MART-1 (Novocastra, Newcastle, UK), T311
(Chen et al, 1995) was used as antibody against tyrosinase and
TA099 (Chen et al, 1995) was the antibody against TRP-1. We (De
Vries et al, 1997) and others (Chen et al, 1995, 1996) have previ-
ously reported on the specificity of the antibodies used.
Consecutive sections of all melanocytic lesions were immunohis-
tochemically stained, using the above-mentioned antibodies as
primary antibodies. An incubation in which the first antibody was
omitted, served as a negative control. An ABC-peroxidase method
was used (De Vries et al, 1996, 1997). Antibody binding was
visualized using 3-amino-9-ethylcarbazole as a substrate. After
counterstaining with Meyer's haematoxylin, sections were
mounted with Kaisers glycerin (Merck, Danrnstadt, Germany).
Score
For each section, the percentage of positive melanoma cells was
estimated. Each section was assigned to one ofthe following cate-
gories: 0%. 1-5%, 5-25%, 25-50%, 50-75% and 75-100%.
Positive melanoma staining was scored when at least 1% of the
melanoma cells stained. The scoring was performed independently
by two observers (TJdV, DT). In cases ofadiscrepancy, consensus
could be reached during joint examination with aUl four persons
involved in this study.
DOPA reaction
Parallel to the immunohistochemical staining, we used the enzyme
histochemical DOPA reaction to confirm tyrosinase activity in aUl
lesions. Adjacent4-pmcryostat sections were stained forimmuno-
histochemistry and for the DOPA reaction. L-DOPA (1 mg ml-')
(3,4-dihydroxy-L-phenylalanine; Sigma, Bernhem, Belgium) was
dissolved in 0.1 M phosphate buffer pH 7.4. The reaction was
stopped after 4 or 6 h. Incubations without substrate served as a
negative control. Positive reactions showed a black precipitate in
the tumour cells.
RESULTS
Eleven spindle-type uveal melanomas. 21 mixed and purely
epithelioid uveal melanomas (both mixed and epithelioid tumos
contain epithelioid cells) and four metastases from uveal
melanoma were stained with antibodies against gplOO, MART-1,
tyrosinase and TRP-1. Representative examples are shown in
Figure 1. The scoring results of the primary tumours are depicted
in Figure 2. Staining results of the four metastases are shown in
Table 1. All antibodies used recognized normal uveal melanocytes
and retinal pigment epithelial cells present in the lesions (results
not shown, see also DOPA-positive retinal pigment epithelium in
Figure 3).
All primary tumours (Figure 2) and all metastases (Table 1)
expressed gplOO, MART-1, tyrosinase and TRP-1. Expression of
gplOO, MART-I and tyrosinase was very high in both the spindle-
type melanomas and in the mixed and epithelioid melanomas
(Figure 2): 75-100% of tumour cells stained homogeneously
strong in approximately 80% ofthe lesions. TRP-1 expression was
strong but was slightly less in both types of tnmours. The few
metastases that we could include in this series featured high
expression of MART-1 and tyrosinase and diminished expression
ofgpl00 and TRP-1 (Table 1).
Within the individual tumours, simultaneous staining forall four
antigens was observed in the majority of the cases, although
heterogeneity of staining was also found. Homogeneously strong
staining for gplOO (Figure lA), TRP-1 (Figure IB) and tyrosinase
(Figure 1C and D being the negative control staining for this
lesion) in three different primary tunours is shown. Similar strong
and homogenous MART-I expression was observed in many
primary tumos (not shown). Individual tumourcells invading the
sclera (Figure IE) could be detected with all five antibodies.
Heterogeneity of staining was found in two metastases (Figure
IF-J). One metastasis (Figure 1F-G) showed strong MART-1
(Figure IF) and tyrosinase (not shown) staining whereas no
TRP-1 (Figure 1G) norgplOO (not shown) could be detected in the
area shown. In other areas in these two lesions, however, a limited
expression was found (not shown). The odter metastasis (Figure
1H-J) showed strong homogeneous staining for MART-1 (Figure
1H) and tyrosinase (not shown), strong but localized TRP-I
staining (Figure 11) and scattered gplOO positivity (Figure 1J).
A DOPA-reaction was performed for all lesions and confirmed
the tyrosinase immunohistochemical results except for two
primary tumours where the DOPA-positive area exceeded the
tyrosinase immunohistochemical positive area. Immunohisto-
chemistry and DOPA confirmed one another in all other primary
tumours and all metastases. An example of the DOPA staining is
shown in Figure 3. Both tumour cells and retinal pigment epithe-
lial cells reacted with the tyrosinase enzyme substrate.
DISCUSSION
In this study, we describe the abundant presence of the
immunoteapy candidate proteins gplOO, MART-1, tyrosinase
and TRP-1 in primary and metastatic uveal melanoma lesions.
Upon discovery ofhepatic metastases, usually by fine-needle aspi-
ration, the time ofsurvival of a uveal melanoma patient is dramat-
ically low, usually between 2 and 4 months (Gamel et al, 1993).
Therefore, a search for new therapies is warranted. One possibility
is to apply what has recently been implemented experimentally in
the reatment of cutaneous melanoma patients. Experimental
immunotherapeutical devices either using peptides or(autologous)
whole-cell vaccinations are being implemented. Several lines of
evidence indicate that uveal melanoma can respond similarly to
immunological stimuli: (1) lymphocytes cytotoxic to both uveal
and cutaneous melanoma cell lines have been isolated from the
blood ofocular melanoma patients (Kan-Mitchell et al, 1991); (2)
tumour-infiltrating lymphocytes from uveal melanoma tumours








Figure 1 Examples of ir n sting forgp1OO, MART-i, tys e and TRP-1 in pmary and e c uveal meanoma lesions. Exression in pmary tours (A-E) and in rnetastases (F-J) iS Shon. Homogeneous sbong staiing forgpl00 with antbodyNKI4beteb (A), TRP-1 (B), tyrosnae (C) and its negative contro (D) in the different primary tumos is displayed. Tumor cels iwading the scera (E) stained with HMB-45 are shown; posifive uivang cels coUd be detected with e oherfourantibodieswitin te same area inconmecut sections. Stann in two metstases (F-G, H-J) in
one case shows high expression of MART-1 (F) and no TRP-1 (G) in the area shown. The other meas (H-J) expressed high MART-1 lvels (H), bwer expression of TRP-1 (1) and scattered gp1OO positivity (J, arrowhead). Note that fe MART-1 staining (H) is alsopostive in the area negative forTRP-1 (arrowhead). Bar = 25Wim in C, D, F and G; bar = 50[tm in A, B, E, HJ.
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Figure 2 gpl00, MART-i tyrosinase and TRP-1 expression in 32 primary uveal melana lesions expressed as a percentage of immunoreactive cells. Each
immunohistochemically stained lesion was assigned to a percentage of positive melanoma cells. Antibodies against gpl00 (HMB-45 and NKI-beteb), MART-1
(A103), tyrosinase (T311) and TRP-1 (TA099) are listed
Table 1 Percentage of positive tumour cells in uveal melanoma metastases after immunohistochemica] staining
Antigen gp100 MART-1 Tyrosinase TRP-1
Antibody code A103 T311 TA099
HMB-45 NKI-beteb
Metastases
Case 1 (parotis) 75-100 75-100 75-100 75-100 50-75
Case 2(lyph node) 75-100 75-100 75-100 75-100 5-25
Case 3 (brain) 1-5 1-5 75-100 75-100 1-5
Case 4 (skin) 5-25 5-25 75-100 75-100 5-25
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Figure 3 Tyrosinase enzyme actvity as determined with the DOPA-reacton. (A) A black precipitate is formed in both tumour cells and retinal pigment
epithelial cells (arrowhead). (B) Negative control consecutive section incubated with PBS wifthout substrate. Bar = 50 im
protect against metastatic load in nude mice injected with ux-eal
melanoma cells (Ma and Niederkom. 1995): and (3) injection with
anti-ganglioside antibodies protects against metastatic spread in
mice with transgenic ocular tumours (Niederkom et al. 1993).
We therefore studied the expression of immunotherapy candi-
date proteins gp 00. MART-1. tyrosinase and TRP-I in 32 primary
ux-eal melanomas and four metastases. Although expression of
gplOO in uveal melanomas was studied some time ago (Van der
Pol et al. 1987: Ringens et al. 1989: Steuhl et al. 1993). knowledge
of expression of the other three proteins is lacking. Mulcahy et al
(1996) previously reported that gplOO. MART-1 and tyrosinase
mRNA was present in all 27 primary uveal melanomas included in
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their study. Our study confirms their findings and substantiates
them. We found very high expression ofall fourproteins studied in
uveal melanoma lesions.
Metastatic uveal melanoma tissue is hard to obtain, as the liver is
the primary metastatic site ofuveal melanoma and these metastases
are discovered relatively late (Gamel et aL 1993). In the few metas-
tases that we could include, we found a mi ed expression of
gplOO and TRP-1 compared with the high expression oftyrosinase
and MART-1. Mulcahy et al (1996) found gplOO. MART-1 and
tyrosinase mRNA in all 26 metastases in their study, athough not
every RT-PCR gave an equally strong result. For opimal
immunotherapeutical purposes, a high proportion of tumour cells
expressing the target antigen is required. Certainly. MAGE-based
vaccinations are unlikely to succeed in the reatment of uveal
melanoma. as uveal melanomas. unlike cutaneous melanomas,
hardly express any members ofthe MAGE gene family (Mulcahy et
al. 1996). With respect to the expression of melanocytic lineage
immunotherapy candidate proteins gplOO. MART-1 tyrosinase and
TRP-1. uveal melanomas express higher levels of these antigens
compared with cutaneous melanoma as recently studied by us (De
Vries et al. 1997) and oners (Chen et al, 1995). Although a higher
number of uveal melanoma metastases should be studied first the
overall high expression ofall four antigens in all lesions involved in
this study makes uveal melanoma a promising candidate tumour for
immunotherapeutical approaches basedon the useofseveral melano-
cyte lineage target antigens. We foundexpression ofthe fourproteins
in retinal pigment epithelium and in normal uveal melanocytes.
whereby we partially confrmn recent reports (Smith-Thomas et al.
1996: Abe etal 1996) ofexpression ofTRP-l. TRP-2 andtyrosinase
inthese cell types. Expression inthese normal cell types could leadto
caution since melanoma cell recognizing T cells could destroy these
cells in an immunotherapy setting. T-cell clones recognizing a
MART-I peptide have been isolated from patients suffering from
Vogt Koyanagi Harada disease, an inflammatory eye disorder
affecting uveal melanocytes (Sugita et al. 1996). On the odthr hand.
normal reinal pigment epithelial cells do not express HLA-DR
(Chan et al, 1986; Detrick et al, 1986) and therefore may not be
recognized by T lymphocytes. Also, to our knowledge, apart from
vitiligo-like depigmentation ofthe skin (Rosenberg, 1997), no unde-
sired ocular side-effects have been described in immunoerapy of
cutaneous melanoma.
ACKNOWLEDGEMENTS
We gratefully thank Dr Lloyd Old and DrElisabeth Stockert at the
Ludwig Institute for Cancer Research, New York Unit at Sloan-
Kettering Cancer Center. New York, USA. for generous supply of
antibodies against MART-1 (A103), tyrosinase (T311) and TRP-1
(TA99). This work was supported by the Dutch Cancer Society,
NUKC 95-912, and partially by the Slovak Grant Agency, grant
number 403 1/97. Dagmar Trancikova received a stipend from the
European Association for Cancer Research for travel and housing
expenses.
REFERENCES
Abe T. Durlu YK and Tamai M (1996) The properties ofretinal pigment epithelial
cells in proliferative Vitreoreninopathy compared with cultured retinal pigment
epithelial cells. Exp Eve Res 63: 201-210
Adema GJ. De Boer AJ. Van t HullenaarR. Denijn M. Ruiter DJ. Vogel AM and
Figdor CG (1993) Melanocyte lineage-specific antigens recognized by
monoclonal antibodies NKI-4eteb. HMB-50. and HMB-45 are encoded by a
single cDNA. Am J Pathol 143: 1579-1585
Bakker ABH. Schreurs MWJ. De Boer AJ. Kawakami Y. Rosenberg SA. Adema GJ
and Figdor CG (1994) Melanocvte lineage-specific antigen gpl00 is
recogized by melanoma-derived tumor-infiltting lymphocytes. JErp Med
179 1005-1009
Brichard V. Van Pel A. Wolfel T. Wolfel C. De PIaen E. Lethe B. Coulie P and Boon T
( 1993) The tyrosinase gene codes foran antigen recognized by autologous
cvtolytic Tlymphocytes on HLA-A2 elanomas JEp Med 178: 489-495
Carrel S and Rimokli D (1993) Melanoma-associated antigens. EurJ Cancer29A:
1903-1907
Chan CC. Detrick B. Nussenblat RB. Palestine AG. Fujikawa LS and Hooks JJ
(1986) HLA-DR antigens on retinal pigment epithelial cells from patients with
uveitis. Arch Ophhaluol 104: 725-729
Chen C-T. Stockert E. Tsang S. Coplan KA and Old U (1995) Immunophenotyping
of melanomas for tyrosinase: Implications for vaccine development Proc Natl
AcadSci UISA 92: 8125-8129
Chen C-T. Stockert E. Jungblut A. Tsang S. Coplan KA. Scanlan MJ and Old U
(1996) Serological analysis ofMelan-A(MART-1). a melanocyte-specific
protein homogeneously expressed in human melanomas. Proc NatlAcad Sci
ULSA 1q9: 5915-5919
De Vries TJ. Verheijen JH. De Bart ACW. Weidle THL Ruiter DJ and Van
Muijen GNP (1996) Decreased expression ofboth the low-density lipoprotein
receptor-related protein/alpha2-macroglobulin receptor and its receptor
associated protein in late stages ofmelanocytic tumorprogression. Cancer Res
56:1432-1439
De Vries TJ. Fourkour A. Wobbes T. Verkroost G. Ruiter DJ and Van Muijen GNP
(1997) Heterogeneous expression of immunotherapy candidate proteins gpl00.
MART-I and nTrosinase in human melanoma cell lines and in human
melanoc,tic lesions. Cancer Res 57: 3223-3229
Detrick B. Rodtiques M. Chan CC. Tso MO and Hooks JJ (1986) Expression of
HLA-DR antigen on retinal pigment epithelial cells in retinitis pigmentosa Am
JOpihalmol 101: 584-590
Foss AJE. Guille M1. Occleston N]L Hvkin PG. Hungerford JL and Lightman S
(1995) The detection ofmelanoma cells in peripheral blood by reverse
transcripion-polvmerase chain reaction. BrJ Cancer 72: 155-159
Gamel JW, McLean IW and McCurdc JB (1993) Biologic distinctons bet-een cure
and time to death in'2892 patients with intraocular melanoma Cancer 71:
2299-2305
Kan-Mitchel J, Rao N. Albert D. Van Eldik U and Taylor CR (1990) S100
immunophenotypes ofuveal melanomas. Invest OphthaLmol VLtS Sci 31:
1492-1496
Kan-Mitchell J. Liggett PE. Harel W. Stinman L Nitta T. Oksenberg JR. Posner
MR and Mitchell MS (1991) Lymphocytes cytotoxic to uveal and skin
melanoma cells from peipheral blood ofocular melanomapatients. Cancer
ImmunolImmwzodher33: 333-340
Kawakami Y, Eliyahu S. Sakaguchi K. Robbins PF. Rivohtini L Yanelli JB. Appella
E and Rosnberg SA (1994) Identifiation ofthe immunodominant peptides of
the MART-I human melanoma antigen recognized by the majority ofHLA-A2
resicted tumor infilrating lymphocy JExp Med 179: 347-352
Ma D and Niederkoen JY (1995) Efficacy oftunor-infiltating lymphocytes in the
reatment ofhepatic metastases arising fom transgenic intraotular tumors in
mice. Invest Ophabol Vis Sci36: 1067-1075
Mulcahy KA. Rimokdi D. Brasseur F, Rodgers S. Lienard D. Marchand M. Rennie
IG. Murray AK. McIntyre CA. Plans KE. Leyvraz S. Boon T and Rees RC
(1996) Infrequent expression ofthe MAGE gene family in uveal melanomas.
IntJ Cancer66: 738-742
Natali PG. Bigotti A. Niora MR. Nardi RM. Delovu A. Segatto 0 and Ferrone S
(1989) Analysis ofthe antigenic profile ofuveal melanoma lesions with anti-
cutaneous melanoma-assoiated antigen and anti-HLA monoclonal antibodies.
CancerRes49: 1269-1274
Niederkom IY. Mellon J. Pidhxrny NM Mayhew E. and Anand R (1993) Effect of
anti-ganglioside antibodies on the metastatic spread ofintraocular melanomas
in a nude mouse model ofhuman uveal melanoma CurrEve Res 12: 347-358
Ringens PJ. Van Haperen R. VennegoorC. De Jong FTVM. Van Duinen SG. Ruiter
DJ and Van der Kamp AWM (1989) Monoclonal antibodies in detection of
choroidal melanoma Graefe sArrhive Ophthalmol 227: 287-290
Rosenberg SA (1997) Cancer vaccines based on the identificatin ofgenes encoding
cancer regression antigens. ImmJnol Today 18: 175-181
Ruiter DJ and Brocker E-B (1993) Immunohistochemistry in the evaluation of
melanocytic tumors. Semin Diagn Pathol 10: 76-91
Smith B. Selby P. Southgate J. Pittman K. Bradley C and Blair GE (1991) Detection
ofmelanoma cells in peripheral blood by means ofreverse tansciptase and
polymerase chain reaction. e 338: 1227-1229
British Journal ofCarner (1998) 78(9), 1156-1161 0CancerResearch Campaign 1998Immunotherapymarkers in uvealmelanoma 1161
Smith-Tbomas L Richardson P. Tody AJ. Graham A. Palmer L Fkmming L
Parsons MA. Rennie IG and MacNeil S (1996) Human ocularmeanocytes and
retinal pigment epithelial cells differ in dteir melanogeni properties in vivo
and in vitro. CurrEve Res 15: 1079-1091
Steuhl K-P. Rohrbach JM, Knorr M and Thiel H-J (1993) Significance. specificity.
and ultrastructural localizato ofHMB-45 antigen in pigmented ocular tumors.
Ophhalbology 1W. 208-215
Sugita S. Sagawa K. Mochizuki NI. Shichijo S and Itoh K (1996) Melanocyte lysis
by cytotoxic T lymphocytes recognizing the MART 1 melanoma antigen in
HLA A2 patients with Vogt Koyanagi Harada disease. nt Imnurol 8: 799-803
Tobal K. Sherman LS. Foss AJE. Lightman SL (1993) Dectuion ofmelanocytes
from uveal melanoma in perpheral blood using the polymerase chain rection
Invest Ophthalmol Ws Sci 34:_6"2-2625
Van der Pol JP Jager MJ. De Wolff-Rouendaal D. Ringens Pl. VennegoorC and
Ruiter DJ (1987) Heterogeneous expression ofmelanoma-associated antigens
in uveal melanomas. Current Eve Res 6: 757-765
Wang R-F. Parkhurst MR. Kawaklami Y. Robbins PF and Rosenberg SA (1996)
Utilization ofan aternative open reading frame ofa normal gene in generating
a novel human cancer antigen- JErp Med 183: 1131-1140
C CancerResearch Campaign 1998 BritshJournalofCancer(1998) 78(9), 1156-1161